Formulations having anti-inflammatory activity and antimicrobial activity against gram-positive bacteria
Novel active compositions having antimicrobial and anti-inflammatory activity are described, the activity provided by an active component prepared in a suspension, the active component being at least a single chain fatty acid having a carbon length of 12, or between 12 and no more than 18. The fatty acid may be esterified and/or ethylated or methylated. As an antimicrobial the active component has activity against one or more microorganisms including Staphylococcus spp., Streptococcus spp., Mycobacterium spp., Clostridium spp., and Candida spp., with an MIC as low as 0.0018 μg/ml. As an anti-inflammatory, it is at least as or is more effective than cyclosporine in preventing T-cell proliferation in response to a trigger, such as stimulation by the one or more microorganisms. The active component is more active when combined with a phospholipid (e.g., lecithin, phosphatidylcholine) and caused to form liposomal nanoparticles. It is also more active when caused to form coated liposomal nanoparticles. Compositions with said active components may be provided internally and/or topically on a surface or on skin.
1. A composition with microbial growth inhibitory activity, the composition comprising:
an active component of esterified fatty acids, the esterified fatty acids being selected from one of ethyl dodecanoate and methyl dodecanoate, wherein the active component is in a total amount up to about 50 wt. % of the composition;
an organic carboxylic acid as a solvent having a pH of between about pH 4 and pH 6; and
phospholipids in an amount between about 0.5 and 50 wt. % of the composition, wherein the phospholipids are one of: (i) neutral phospholipids, and (ii) neutral phospholipids combined with at least one of a double chain phospholipid and cholesterol; and
wherein the composition is in a suitable form for pharmacotherapy use as an antimicrobial, wherein the suitable form for pharmacotherapy use comprises at least one of a powder, particulate, gel, and suspension,
wherein the composition is caused to form liposomes containing at least the phospholipids and the active component, and
wherein the suitable form is active against and has growth inhibitory activity against pathogenic Gram-positive bacteria and yeast selected from at least one strain of at least one of Staphylococcus spp., Streptococcus spp., Mycobacterium spp., Clostridium spp. and Candida spp. without targeting beneficial natural Gram-positive bacteria selected from any one or more of Lactobacillus acidophilus and Bifidobacterium bifidum , wherein at least one strain of at least one of the pathogenic Gram-positive bacteria and yeast is resistant to another and different class of antimicrobial.
2. The composition of claim 1 , wherein the phospholipids are one or more of: phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidic acid, phosphatidylserine, lysophospholipid, and any combination thereof.
3. The composition of claim 1 , wherein, excluding the active component, the composition comprises no additional free fatty acids having a carbon chain length from 6 to 12.
4. The composition of claim 1 , wherein the esterified fatty acids are one or more of having a purity of about or greater than 90%, and having a pharmaceutical grade purity.
5. The composition of claim 1 , wherein the composition further comprises at least one fatty acid having a carbon chain length from between 13 to 18.
6. The composition of claim 1 , wherein the suitable form is any one or more of lyophilized, suitable for storing, and stable at ambient or room temperature.
7. The composition of claim 1 , wherein the suitable form is for internal use by a subject in need thereof.
8. The composition of claim 1 , wherein the suitable form is for topical use by a subject in need thereof.
9. The composition of claim 1 , wherein the suitable form inhibits growth of at least two strains from a group consisting of Staphylococcus spp., Streptococcus spp., Mycobacterium spp., Clostridium spp. and Candida spp.
10. The composition of claim 1 , wherein, when the active component is provided in an amount and at an MIC for growth inhibitory activity against at least one of the pathogenic Gram-positive bacteria and yeasts, or in an amount that is greater than the amount at the MIC for growth inhibitory activity against at least one of the pathogenic Gram-positive bacteria and yeasts, the suitable form is selectively active against at least one strain of at least one of a susceptible Gram-positive bacteria and yeast without targeting beneficial Gram-positive bacteria from one or more of oral mucosa, skin, and gastrointestinal tract.
11. A composition having microbial growth inhibitory activity, the composition comprising:
an active component of esterified fatty acids, the esterified fatty acids being selected from one of ethyl dodecanoate and methyl dodecanoate, the esterified fatty acids in an amount up to about 50 wt. % of the composition; and
phospholipids in an amount between about 0.001 and 50 wt. % of the composition, wherein the phospholipids are one of: (i) neutral phospholipids, and (ii) neutral phospholipids combined with at least one of a double chain phospholipid and cholesterol; and
wherein the composition is in a suitable form for pharmacotherapy use as an antimicrobial,
wherein the suitable form comprises at least liposomal nanoparticles comprising at least the active component and the phospholipids,
wherein the suitable form is active against and has growth inhibitory activity against pathogenic Gram-positive bacteria and yeast selected from at least one strain from at least one from a group consisting of Staphylococcus spp., Streptococcus spp., Mycobacterium spp., Clostridium spp. and Candida spp. without targeting beneficial natural Gram-positive bacteria selected from any one or more of Lactobacillus acidophilus and Bifidobacterium bifidum , wherein at least one strain of at least one of the pathogenic Gram-positive bacteria and yeast is resistant to another and different class of antimicrobial,
and wherein the composition is formed by at least the steps of:
combining the active component, an organic acid as a solvent, and the phospholipids, the organic acid having fewer than 3 linear carbons and a pH between about pH 4 and about pH 6; and
suspending and causing to form liposomes, wherein the liposomes contain at least the active component and the phospholipids.
12. The composition of claim 11 , wherein the phospholipids are neutral phospholipids combined with at least cholesterol, and the cholesterol is in an amount between about 0.04 and 6 wt. % of the composition.
13. The composition of claim 11 , wherein the phospholipids are one or more of: phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidic acid, phosphatidylserine, lysophospholipid, and any combination thereof.
14. The composition of claim 11 , wherein the organic acid is any one of a weak short chain carboxylic acid, and a buffered weak short chain carboxylic acid.
15. The composition of claim 11 , wherein the step of combining comprises at least one of: (i) combining the active component with the phospholipids and the organic acid; (ii) combining initially the phospholipids and the organic acid before adding the active component; (iii) combining the active component with the phospholipids and the organic acid, which is followed by at least a step of filtering; and (iv) combining initially the phospholipids and the organic acid before adding the active component, which is followed by at least a step of filtering.
16. The composition of claim 11 , wherein the suitable form is for internal use by a subject in need thereof.
17. The composition of claim 11 , wherein the suitable form is for topical use by a subject in need thereof.
18. The composition of claim 11 , wherein the liposomal nanoparticles are lyophilized.
19. The composition of claim 11 , wherein the liposomal nanoparticles are in a pharmaceutical formulation intended for internal administration to a subject in need thereof, for inhibiting growth of at least one strain of at least one of the pathogenic Gram-positive bacteria and yeast.
20. The composition of claim 11 , wherein the liposomal nanoparticles are in a pharmaceutical formulation intended for topical administration to a subject in need thereof, for inhibiting growth of at least one strain of at least one of the pathogenic Gram-positive bacteria and yeast.